More information is needed on an anthrax treatment before the effectiveness of the drug against its anti-bacterial rivals can be assessed, the Federal licensing body has said.
A panel of 23 experts at the Food and Drug Administration (FDA) voted 17-6 that more evidence should be submitted before ABthrax can be added to the list of drugs to treat anthrax. While, the vote is not formally binding, it usually sets the panel’s decision.
ABthrax is produced by Maryland-based Human Genome Sciences for the treatment of Anthrax, a diseases caused by bacteria in the body of transmission from toxic spores.
Human Genome Sciences’ own studies showed that antibiotic medicines used alone were highly effective against anthrax, raising questions about the added benefit of ABthrax.
Copyright Press Association 2009
ABthrax drug application